Contineum Therapeutics (CTNM) Competitors $3.77 +0.04 (+1.07%) Closing price 07/15/2025 04:00 PM EasternExtended Trading$3.94 +0.18 (+4.64%) As of 07/15/2025 06:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CTNM vs. TECX, SLDB, ITOS, ETON, ALT, CMPX, CYRX, RVNC, VIGL, and CTORShould you be buying Contineum Therapeutics stock or one of its competitors? The main competitors of Contineum Therapeutics include Tectonic Therapeutic (TECX), Solid Biosciences (SLDB), iTeos Therapeutics (ITOS), Eton Pharmaceuticals (ETON), Altimmune (ALT), Compass Therapeutics (CMPX), CryoPort (CYRX), Revance Therapeutics (RVNC), Vigil Neuroscience (VIGL), and Citius Oncology (CTOR). These companies are all part of the "pharmaceutical products" industry. Contineum Therapeutics vs. Its Competitors Tectonic Therapeutic Solid Biosciences iTeos Therapeutics Eton Pharmaceuticals Altimmune Compass Therapeutics CryoPort Revance Therapeutics Vigil Neuroscience Citius Oncology Tectonic Therapeutic (NASDAQ:TECX) and Contineum Therapeutics (NASDAQ:CTNM) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, analyst recommendations, profitability, institutional ownership, dividends, media sentiment and valuation. Which has more risk and volatility, TECX or CTNM? Tectonic Therapeutic has a beta of 3.17, suggesting that its share price is 217% more volatile than the S&P 500. Comparatively, Contineum Therapeutics has a beta of 0.85, suggesting that its share price is 15% less volatile than the S&P 500. Is TECX or CTNM more profitable? Contineum Therapeutics' return on equity of -24.59% beat Tectonic Therapeutic's return on equity.Company Net Margins Return on Equity Return on Assets Tectonic TherapeuticN/A -30.13% -27.52% Contineum Therapeutics N/A -24.59%-23.49% Which has preferable earnings and valuation, TECX or CTNM? Tectonic Therapeutic is trading at a lower price-to-earnings ratio than Contineum Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTectonic TherapeuticN/AN/A-$57.98M-$7.31-2.93Contineum TherapeuticsN/AN/A-$42.26M-$1.97-1.91 Do analysts prefer TECX or CTNM? Tectonic Therapeutic presently has a consensus price target of $83.60, suggesting a potential upside of 289.93%. Contineum Therapeutics has a consensus price target of $22.50, suggesting a potential upside of 496.82%. Given Contineum Therapeutics' higher probable upside, analysts plainly believe Contineum Therapeutics is more favorable than Tectonic Therapeutic.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tectonic Therapeutic 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 2 Strong Buy rating(s) 3.33Contineum Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.17 Do insiders and institutionals hold more shares of TECX or CTNM? 62.6% of Tectonic Therapeutic shares are owned by institutional investors. 9.2% of Tectonic Therapeutic shares are owned by company insiders. Comparatively, 11.3% of Contineum Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Does the media favor TECX or CTNM? In the previous week, Contineum Therapeutics had 2 more articles in the media than Tectonic Therapeutic. MarketBeat recorded 3 mentions for Contineum Therapeutics and 1 mentions for Tectonic Therapeutic. Tectonic Therapeutic's average media sentiment score of 1.87 beat Contineum Therapeutics' score of 1.41 indicating that Tectonic Therapeutic is being referred to more favorably in the media. Company Overall Sentiment Tectonic Therapeutic Very Positive Contineum Therapeutics Positive SummaryContineum Therapeutics beats Tectonic Therapeutic on 9 of the 14 factors compared between the two stocks. Get Contineum Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CTNM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CTNM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CTNM vs. The Competition Export to ExcelMetricContineum TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$96.50M$2.96B$5.62B$9.30BDividend YieldN/A2.43%4.25%4.03%P/E Ratio-1.9120.2228.5719.58Price / SalesN/A289.98423.3593.43Price / CashN/A43.1536.0257.93Price / Book0.497.568.135.54Net Income-$42.26M-$55.11M$3.24B$257.73M7 Day Performance-5.99%3.81%0.16%-0.08%1 Month Performance-12.12%11.60%5.95%8.09%1 Year Performance-82.67%-2.11%26.09%13.02% Contineum Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CTNMContineum Therapeutics3.6342 of 5 stars$3.77+1.1%$22.50+496.8%-82.0%$96.50MN/A-1.9131News CoveragePositive NewsTECXTectonic Therapeutic2.4865 of 5 stars$20.78-2.6%$83.60+302.3%+28.8%$398.47MN/A-2.84120Positive NewsSLDBSolid Biosciences3.4467 of 5 stars$4.91-2.4%$15.10+207.5%-37.0%$389.90M$8.09M-1.64100ITOSiTeos Therapeutics3.3048 of 5 stars$10.07-1.1%$15.86+57.5%-37.9%$389.63M$35M-3.3190ETONEton Pharmaceuticals2.1092 of 5 stars$14.39-0.4%$29.67+106.2%+332.0%$387.51M$39.01M-79.9420ALTAltimmune2.1982 of 5 stars$4.43-6.9%$19.00+328.9%-47.1%$386.07M$20K-3.5250CMPXCompass Therapeutics3.04 of 5 stars$2.64-5.0%$12.67+379.8%+195.0%$384.43M$850K-6.4420News CoveragePositive NewsCYRXCryoPort2.096 of 5 stars$7.29-4.8%$10.88+49.2%-1.3%$384.05M$228.38M-3.121,186Gap DownRVNCRevance Therapeutics2.6227 of 5 stars$3.65flat$8.45+131.5%N/A$381.02M$234.04M-1.89500VIGLVigil Neuroscience3.6991 of 5 stars$7.99flat$10.80+35.2%+91.9%$381.02MN/A-3.9040CTORCitius Oncology1.6719 of 5 stars$4.71-11.0%$3.00-36.3%N/A$378.51MN/A0.00N/ANews CoverageGap Up Related Companies and Tools Related Companies TECX Competitors SLDB Competitors ITOS Competitors ETON Competitors ALT Competitors CMPX Competitors CYRX Competitors RVNC Competitors VIGL Competitors CTOR Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CTNM) was last updated on 7/16/2025 by MarketBeat.com Staff From Our Partners3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhy Elon is funding the “Quantum Power Grid”Elon knows the future isn’t about smarter AI — it’s about powering it. And this new technology is quietly b...True Market Insiders | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredThis Social Security Shift Could Boost Benefits by 400%If you currently collect Social Security—or plan to in the future—this may be one of the most important update...InvestorPlace | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Contineum Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Contineum Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CTNM Stock Alerts